ClinicalTrials.gg
CompletedNCT05083949InPedILD®Updated Jul 27, 2023Results posted

A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together

A Phase 1 interventional study of FDC 12.5mg empagliflozin/850mg metformin and Empagliflozin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Brazil. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This trial is to establish bioequivalence of the fixed dose combination (FDC) tablets (containing 12.5 mg empagliflozin/850 mg metformin) (Test, T) compared with the single tablets (10 mg empagliflozin and Glifage® 850 mg tablets) (Reference, R).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of at least 18 (inclusive) to 50 years (inclusive)
  • (BMI) of 18.5 to 29.9 weight divided by height squared (kg/m2) (inclusive)
  • Signed and dated written prior to admission to the study, in accordance with Good Clinical Practice (GCP) and local legislation
  • Male subjects, or female subjects who meet any of the following criteria from at least 30 days before the first administration of trial medication until 30 days after trial completion:
  • Use of adequate , e.g. any of the following methods plus condom:

    • implants, injectables, combined oral or vaginal contraceptives, intrauterine device
    • Sexually abstinent
    • A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)
    • Surgically sterilised (including hysterectomy)

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • Use of drugs within 30 days of planned administration of trial medication that might reasonably influence the results of the trial (including drugs that cause time from the start of the Q wave to the end of the T wave () / corrected QT (QTc) interval prolongation)
  • Smoker (more than 5 cigarettes or 1 cigar or 1 pipe per day)
  • Detection or indeterminate / inconclusive result of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus ribonucleic acid (RNA) in the quantitative real-time polymerase chain reaction (RT-qPCR) exam performed on the day before the admission of each period;
  • The research participant presents symptoms of coronavirus disease 2019 (COVID-19) infection (even if the result is "undetected" in the RT-PCR exam for COVID-19)
  • Further exclusion criteria apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    (A): empagliflozin 10mg (R1)+Glifage® 850mg (R2),then (B): FDC 12.5mg empagliflozin/850mg metformin

    On Day 1 of Period 1 subjects received treatment A: Single dose tablet of 10 milligram(mg) empagliflozin film-coated and a 850mg of metformin hydrochloride (HCl) (Glifage®) tablet, orally with 200 milliliter(mL) of water. On Day 1 of Period 2 subjects received treatment B: Fixed dose combination (FDC) tablet of 12.5mg empagliflozin/850 mg metformin HCl, orally with 200mL of water. A high-fat, high-calorie meal was served 30 minutes(min) before drug administration. The treatments were separated by a wash-out phase of at least 7 days.

    Drug: FDC 12.5mg empagliflozin/850mg metformin · Drug: Empagliflozin · Drug: Glifage®

  • Experimental
    (B): FDC 12.5mg empagliflozin/850mg metformin,then (A): empagliflozin 10mg(R1) + Glifage® 850mg(R2)

    On Day 1 of Period 1 subjects received treatment B: Fixed dose combination (FDC) tablet containing 12.5 milligram (mg) empagliflozin/850 mg metformin HCl, orally with 200 milliliter (mL) of water. On Day 1 of Period 2 subjects received treatment A: Single dose tablet of 10mg empagliflozin and 850 mg of metformin hydrochloride (HCl) (Glifage®) tablet, orally with 200mL of water. A high-fat, high-calorie meal was served 30 minutes (min) before drug administration. The treatments were separated by a wash-out phase of at least 7 days.

    Drug: FDC 12.5mg empagliflozin/850mg metformin · Drug: Empagliflozin · Drug: Glifage®

Interventions

  • DrugFDC 12.5mg empagliflozin/850mg metformin

    empagliflozin/metformin

  • empagliflozin 10mg (R1)

  • Glifage® 850mg (R2)

    Also known as: metformin

06

What researchers measure

Primary outcomes

  1. Dose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) normalized to the actual administered dose is presented. The AUC0-tz was divided by the actual dose strength to get the normalized area under the concentration-time curve. The statistical model used for the analysis of the primary endpoints was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed. Unit of measure:(hour\*nanogram/milliliter)/milligram.

    Time frame: Within 5 minutes (min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  2. Dose-normalized Maximum Measured Concentration of Empagliflozin (Cmax)

    Dose-normalized Maximum measured concentration of empagliflozin in plasma is presented. The maximum measured concentration was divided by the actual dose strength to get the dose-normalised Cmax. The statistical model used for the analysis of the primary endpoints was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed. The unit of measure reported is: (nanogram/milliliter)/milligram.

    Time frame: Within 5 minutes (min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  3. Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is presented. The statistical model used for the analysis of the primary endpoints was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  4. Maximum Measured Concentration of Metformin (Cmax)

    Maximum measured concentration of metformin in plasma is presented. The statistical model used for the analysis of the primary endpoints was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

Secondary outcomes

  1. Dose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞ )

    Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 extrapolated to infinity from the last quantifiable data point (AUC0-inf) normalized to the actual administered dose is presented. The AUC0-oo was divided by the actual dose strength to get the normalized area under the concentration-time curve. The statistical model used for the analysis of the primary endpoints was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed. Unit of measure: (hour\*nanogram/milliliter)/milligram.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  2. Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞ ) is presented. The statistical model used for the analysis was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  3. Time From Last Dosing to the Maximum Measured Concentration of Empagliflozin in Plasma (Tmax)

    Time from last dosing to the maximum measured concentration of empagliflozin in plasma (tmax) is presented.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  4. Time From Last Dosing to the Maximum Measured Concentration of Metformin in Plasma (Tmax)

    Time from last dosing to the maximum measured concentration of metformin in plasma (tmax) is presented.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  5. Percentage (%) of the AUC of Empagliflozin That Has Been Derived After Extrapolation

    The percentage (%) of the AUC of empagliflozin that has been derived after extrapolation is reported.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  6. Percentage (%) of the AUC of Metformin That Has Been Derived After Extrapolation

    The percentage (%) of the AUC of metformin that has been derived after extrapolation is reported.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  7. Terminal Half-life of Empagliflozin in Plasma (t1/2)

    The terminal half-life of empagliflozin in plasma (t1/2) is presented.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  8. Terminal Half-life of Metformin in Plasma (t1/2)

    The terminal half-life of metformin in plasma (t1/2) is presented.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  9. Elimination Rate Constant (Kel) for Empagliflozin

    The elimination rate constant (Kel) for empagliflozin is reported.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

  10. Elimination Rate Constant (Kel) for Metformin

    The elimination rate constant (Kel) for metformin is reported.

    Time frame: Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.

07

Results

Posted Jul 27, 2023

Participant flow

This was a phase I, randomised, open label, 2x2 crossover trial in healthy male and female subjects to establish the bioequivalence of 1 Fixed dose combination tablet 12.5 mg empagliflozin/850 mg metformin (treatment B) to the reference treatments (treatment A) which consisted in 1 tablet empagliflozin10 mg (Reference 1) + 1 tablet Glifage® 850 mg (Reference 2).

Period 1
Participant flow — Period 1
Milestone(A): Empagliflozin 10mg (R1)+Glifage® 850mg (R2),Then (B): FDC 12.5mg Empagliflozin/850mg Metformin(B): FDC 12.5mg Empagliflozin/850mg Metformin,Then (A): Empagliflozin 10mg(R1) + Glifage® 850mg(R2)
Started1616
Completed1314
Not completed32
Withdrew: Positive doping for tetrahydrocannabinol (thc)21
Withdrew: Adverse event11
Wash-out
Participant flow — Wash-out
Milestone(A): Empagliflozin 10mg (R1)+Glifage® 850mg (R2),Then (B): FDC 12.5mg Empagliflozin/850mg Metformin(B): FDC 12.5mg Empagliflozin/850mg Metformin,Then (A): Empagliflozin 10mg(R1) + Glifage® 850mg(R2)
Started1314
Completed1314
Not completed00
Period 2
Participant flow — Period 2
Milestone(A): Empagliflozin 10mg (R1)+Glifage® 850mg (R2),Then (B): FDC 12.5mg Empagliflozin/850mg Metformin(B): FDC 12.5mg Empagliflozin/850mg Metformin,Then (A): Empagliflozin 10mg(R1) + Glifage® 850mg(R2)
Started1314
Completed1212
Not completed12
Withdrew: The patient was not able to eat the full content of the breakfast10
Withdrew: Adverse event02

Outcome measures

PrimaryDose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) normalized to the actual administered dose is presented. The AUC0-tz was divided by the actual dose strength to get the normalized area under the concentration-time curve. The statistical model used for the analysis of the primary endpoints was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed. Unit of measure:(hour\*nanogram/milliliter)/milligram.

Time frame:
Within 5 minutes (min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Geometric least squares mean · (h*ng/mL)/mg
Dose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
(h*ng/mL)/mg(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Dose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)117.15 ± NA116.65 ± NA
Statistical analysis
  • (A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2) vs (B): FDC 12.5mg Empagliflozin/850mg Metformin · ANOVA · p = 0.7792 · Ratio of glsm (%): 99.57 · 90% CI 97.03 to 102.19Ratio of Geometric Least Squares Means (GLSM) was calculated as: Fixed dose combination (treatment B)/ free dose combination (treatment A). Standard deviation is actually intra-individual geometric coefficient of variation (gCV \[%\]).
PrimaryDose-normalized Maximum Measured Concentration of Empagliflozin (Cmax)

Dose-normalized Maximum measured concentration of empagliflozin in plasma is presented. The maximum measured concentration was divided by the actual dose strength to get the dose-normalised Cmax. The statistical model used for the analysis of the primary endpoints was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed. The unit of measure reported is: (nanogram/milliliter)/milligram.

Time frame:
Within 5 minutes (min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Geometric least squares mean · (ng/mL)/mg
Dose-normalized Maximum Measured Concentration of Empagliflozin (Cmax)
(ng/mL)/mg(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Dose-normalized Maximum Measured Concentration of Empagliflozin (Cmax)13.42 ± NA13.60 ± NA
Statistical analysis
  • (A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2) vs (B): FDC 12.5mg Empagliflozin/850mg Metformin · ANOVA · p = 0.6493 · Ratio of glsm (%): 101.36 · 90% CI 96.39 to 106.59Ratio of Geometric Least Squares Means (GLSM) was calculated as: Fixed dose combination (treatment B)/ free dose combination (treatment A). Standard deviation is actually intra-individual geometric coefficient of variation (gCV \[%\]).
PrimaryArea Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is presented. The statistical model used for the analysis of the primary endpoints was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Geometric least squares mean · hour*nanogram/milliliter (h*ng/mL)
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour*nanogram/milliliter (h*ng/mL)(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)10299.45 ± NA10467.41 ± NA
Statistical analysis
  • (A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2) vs (B): FDC 12.5mg Empagliflozin/850mg Metformin · ANOVA · p = 0.4710 · Ratio of glsm (%): 101.63 · 90% CI 97.85 to 105.55Ratio of Geometric Least Squares Means (GLSM) was calculated as: Fixed dose combination (treatment B)/ free dose combination (treatment A). Standard deviation is actually intra-individual geometric coefficient of variation (gCV \[%\]).
PrimaryMaximum Measured Concentration of Metformin (Cmax)

Maximum measured concentration of metformin in plasma is presented. The statistical model used for the analysis of the primary endpoints was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Geometric least squares mean · nanogram/milliliter (ng/mL )
Maximum Measured Concentration of Metformin (Cmax)
nanogram/milliliter (ng/mL )(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Maximum Measured Concentration of Metformin (Cmax)1333.58 ± NA1308.39 ± NA
Statistical analysis
  • (A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2) vs (B): FDC 12.5mg Empagliflozin/850mg Metformin · ANOVA · p = 0.4251 · Ratio of glsm (%): 98.11 · 90% CI 94.24 to 102.15Ratio of Geometric Least Squares Means (GLSM) was calculated as: Fixed dose combination (treatment B)/ free dose combination (treatment A). Standard deviation is actually intra-individual geometric coefficient of variation (gCV \[%\]).
SecondaryDose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞ )

Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 extrapolated to infinity from the last quantifiable data point (AUC0-inf) normalized to the actual administered dose is presented. The AUC0-oo was divided by the actual dose strength to get the normalized area under the concentration-time curve. The statistical model used for the analysis of the primary endpoints was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed. Unit of measure: (hour\*nanogram/milliliter)/milligram.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Geometric least squares mean · (h*ng/mL)/mg
Dose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞ )
(h*ng/mL)/mg(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B):FDC 12.5mg Empagliflozin/850mg Metformin
Dose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞ )118.25 ± NA117.64 ± NA
Statistical analysis
  • (A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2) vs (B):FDC 12.5mg Empagliflozin/850mg Metformin · ANOVA · p = 0.7379 · Ratio of glsm (%): 99.49 · 90% CI 96.93 to 102.11Ratio of Geometric Least Squares Means (GLSM) was calculated as: Fixed dose combination (treatment B)/ free dose combination (treatment A). Standard deviation is actually intra-individual geometric coefficient of variation (gCV \[%\]).
SecondaryArea Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞ ) is presented. The statistical model used for the analysis was an analysis of variance (ANOVA) on the logarithmic scale. That is, the PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment. The effect 'subjects within sequences' was considered as random, whereas the other effects were considered as fixed.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Geometric least squares mean · hour*nanogram/milliliter (hr*ng/mL)
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour*nanogram/milliliter (hr*ng/mL)(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)10440.79 ± NA10570.45 ± NA
Statistical analysis
  • (A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2) vs (B): FDC 12.5mg Empagliflozin/850mg Metformin · ANOVA · p = 0.5895 · Ratio of glsm (%): 101.24 · 90% CI 97.40 to 105.24Ratio of Geometric Least Squares Means (GLSM) was calculated as: Fixed dose combination (treatment B)/ free dose combination (treatment A). Standard deviation is actually intra-individual geometric coefficient of variation (gCV \[%\]).
SecondaryTime From Last Dosing to the Maximum Measured Concentration of Empagliflozin in Plasma (Tmax)

Time from last dosing to the maximum measured concentration of empagliflozin in plasma (tmax) is presented.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Median · Hours (hr)
Time From Last Dosing to the Maximum Measured Concentration of Empagliflozin in Plasma (Tmax)
Hours (hr)(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Time From Last Dosing to the Maximum Measured Concentration of Empagliflozin in Plasma (Tmax)2.33 (1.25 to 5.00)2.17 (1.00 to 5.50)
SecondaryTime From Last Dosing to the Maximum Measured Concentration of Metformin in Plasma (Tmax)

Time from last dosing to the maximum measured concentration of metformin in plasma (tmax) is presented.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Median · Hours (hr)
Time From Last Dosing to the Maximum Measured Concentration of Metformin in Plasma (Tmax)
Hours (hr)(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Time From Last Dosing to the Maximum Measured Concentration of Metformin in Plasma (Tmax)4.00 (3.00 to 4.50)4.00 (1.00 to 5.00)
SecondaryPercentage (%) of the AUC of Empagliflozin That Has Been Derived After Extrapolation

The percentage (%) of the AUC of empagliflozin that has been derived after extrapolation is reported.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Mean · Percentage (%)
Percentage (%) of the AUC of Empagliflozin That Has Been Derived After Extrapolation
Percentage (%)(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Percentage (%) of the AUC of Empagliflozin That Has Been Derived After Extrapolation9.77 ± 3.049.31 ± 1.87
SecondaryPercentage (%) of the AUC of Metformin That Has Been Derived After Extrapolation

The percentage (%) of the AUC of metformin that has been derived after extrapolation is reported.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Mean · Percentage (%)
Percentage (%) of the AUC of Metformin That Has Been Derived After Extrapolation
Percentage (%)(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Percentage (%) of the AUC of Metformin That Has Been Derived After Extrapolation14.35 ± 8.5013.04 ± 5.58
SecondaryTerminal Half-life of Empagliflozin in Plasma (t1/2)

The terminal half-life of empagliflozin in plasma (t1/2) is presented.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Median · Hours (hr)
Terminal Half-life of Empagliflozin in Plasma (t1/2)
Hours (hr)(A): Empaglifozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Terminal Half-life of Empagliflozin in Plasma (t1/2)0.08 (0.04 to 0.11)0.08 (0.05 to 0.11)
SecondaryTerminal Half-life of Metformin in Plasma (t1/2)

The terminal half-life of metformin in plasma (t1/2) is presented.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Median · Hours (hr)
Terminal Half-life of Metformin in Plasma (t1/2)
Hours (hr)(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Terminal Half-life of Metformin in Plasma (t1/2)0.06 (0.02 to 0.13)0.06 (0.02 to 0.11)
SecondaryElimination Rate Constant (Kel) for Empagliflozin

The elimination rate constant (Kel) for empagliflozin is reported.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Mean · 1/hours (1/hr)
Elimination Rate Constant (Kel) for Empagliflozin
1/hours (1/hr)(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Elimination Rate Constant (Kel) for Empagliflozin0.93 ± 0.610.84 ± 0.44
SecondaryElimination Rate Constant (Kel) for Metformin

The elimination rate constant (Kel) for metformin is reported.

Time frame:
Within 5 minutes(min) before and 15min, 30min, 45min, 1h, 1h15min, 1h30min, 1h45min, 2h, 2h20min, 2h40min, 3h, 3h30min, 4h, 4h30min, 5h, 5h30min, 6h, 7h, 8h, 10h, 12h, 24h, 48h, and 72h after treatment administration for both arms.
Reported as:
Mean · 1/hours (1/hr)
Elimination Rate Constant (Kel) for Metformin
1/hours (1/hr)(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
Elimination Rate Constant (Kel) for Metformin1.33 ± 2.140.97 ± 1.02

Adverse events

Collected over Up to 14 days after the last treatment administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)0/30 (0%)0/30 (0%)5/30 (16.7%)
(B): FDC 12.5mg Empagliflozin/850mg Metformin0/29 (0%)0/29 (0%)2/29 (6.9%)
Most frequent other events
Most frequent other events
Event(A): Empagliflozin 10mg (R1) + Metformin (Glifage®) 850mg (R2)(B): FDC 12.5mg Empagliflozin/850mg Metformin
White blood cells in urineInvestigations3/300/29
HeadacheNervous system disorders1/302/29
HyperglycaemiaMetabolism and nutrition disorders2/300/29

Baseline characteristics

Treated Set (TS): The treated set included all participants in the research that were randomized and treated with at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)(A): Empagliflozin 10mg (R1)+Glifage® 850mg (R2),Then (B): FDC 12.5mg Empagliflozin/850mg Metformin(B): FDC 12.5mg Empagliflozin/850mg Metformin,Then (A): Empagliflozin 10mg(R1) + Glifage® 850mg(R2)Total
Mean32.0 ± 7.231.7 ± 8.331.8 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)(A): Empagliflozin 10mg (R1)+Glifage® 850mg (R2),Then (B): FDC 12.5mg Empagliflozin/850mg Metformin(B): FDC 12.5mg Empagliflozin/850mg Metformin,Then (A): Empagliflozin 10mg(R1) + Glifage® 850mg(R2)Total
Female8816
Male8816
Race (NIH/OMB)
Race (NIH/OMB)(Participants)(A): Empagliflozin 10mg (R1)+Glifage® 850mg (R2),Then (B): FDC 12.5mg Empagliflozin/850mg Metformin(B): FDC 12.5mg Empagliflozin/850mg Metformin,Then (A): Empagliflozin 10mg(R1) + Glifage® 850mg(R2)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American325
White71118
More than one race639
Unknown or Not Reported000
08

Study locations

1 site
  • Instituto de Ciências Farmacêuticas de Estudos e Pesquisas - ICF
    Goiânia, 74935-530, Brazil
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to:https://www.mystudywindow.com/msw/datasharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Aug 2021, 0 months.

Results were first posted in Jul 2023, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2021
First posted
Oct 19, 2021
StartActual
Jul 23, 2021
Primary completionActual
Aug 6, 2021
CompletionActual
Sep 9, 2021
Results first posted
Jul 27, 2023
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05083949
Responsible party
Sponsor
First posted
Oct 19, 2021
Start date
Jul 23, 2021
Primary completion
Aug 6, 2021
Completion
Sep 9, 2021
Results posted
Jul 27, 2023
Last update
Jul 27, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin

Start the discussion